HEPA Quote, Financials, Valuation and Earnings

Cormedix has a net margin of -- compared to Hepion Pharmaceuticals's net margin of 52.82%. Hepion Pharmaceuticals's return on equity of -- beat Cormedix's return on equity of 23.7%.

Hepion Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 3999900%. On the other hand Cormedix has an analysts' consensus of $19.00 which suggests that it could grow by 70.71%. Given that Hepion Pharmaceuticals has higher upside potential than Cormedix, analysts believe Hepion Pharmaceuticals is more attractive than Cormedix.

Hepion Pharmaceuticals has a beta of 1.688, which suggesting that the stock is 68.792% more volatile than S&P 500. In comparison Cormedix has a beta of 1.581, suggesting its more volatile than the S&P 500 by 58.146%.

Hepion Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cormedix offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hepion Pharmaceuticals pays -- of its earnings as a dividend. Cormedix pays out -- of its earnings as a dividend.

Hepion Pharmaceuticals quarterly revenues are --, which are smaller than Cormedix quarterly revenues of $39.1M. Hepion Pharmaceuticals's net income of -$6.1M is lower than Cormedix's net income of $20.6M. Notably, Hepion Pharmaceuticals's price-to-earnings ratio is -- while Cormedix's PE ratio is 50.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hepion Pharmaceuticals is -- versus 8.32x for Cormedix. Usually stocks with elevated PS ratios are considered overvalued.

Krystal Biotech has a net margin of -- compared to Hepion Pharmaceuticals's net margin of 40.52%. Hepion Pharmaceuticals's return on equity of -- beat Krystal Biotech's return on equity of 13.91%.

Hepion Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 3999900%. On the other hand Krystal Biotech has an analysts' consensus of $208.00 which suggests that it could grow by 38.59%. Given that Hepion Pharmaceuticals has higher upside potential than Krystal Biotech, analysts believe Hepion Pharmaceuticals is more attractive than Krystal Biotech.

Hepion Pharmaceuticals has a beta of 1.688, which suggesting that the stock is 68.792% more volatile than S&P 500. In comparison Krystal Biotech has a beta of 0.675, suggesting its less volatile than the S&P 500 by 32.514%.

Hepion Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Krystal Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hepion Pharmaceuticals pays -- of its earnings as a dividend. Krystal Biotech pays out -- of its earnings as a dividend.

Hepion Pharmaceuticals quarterly revenues are --, which are smaller than Krystal Biotech quarterly revenues of $88.2M. Hepion Pharmaceuticals's net income of -$6.1M is lower than Krystal Biotech's net income of $35.7M. Notably, Hepion Pharmaceuticals's price-to-earnings ratio is -- while Krystal Biotech's PE ratio is 36.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hepion Pharmaceuticals is -- versus 13.43x for Krystal Biotech. Usually stocks with elevated PS ratios are considered overvalued.

Protagenic Therapeutics has a net margin of -- compared to Hepion Pharmaceuticals's net margin of --. Hepion Pharmaceuticals's return on equity of -- beat Protagenic Therapeutics's return on equity of --.

Hepion Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 3999900%. On the other hand Protagenic Therapeutics has an analysts' consensus of -- which suggests that it could grow by 6392.75%. Given that Hepion Pharmaceuticals has higher upside potential than Protagenic Therapeutics, analysts believe Hepion Pharmaceuticals is more attractive than Protagenic Therapeutics.

Hepion Pharmaceuticals has a beta of 1.688, which suggesting that the stock is 68.792% more volatile than S&P 500. In comparison Protagenic Therapeutics has a beta of 0.354, suggesting its less volatile than the S&P 500 by 64.562%.

Hepion Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protagenic Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hepion Pharmaceuticals pays -- of its earnings as a dividend. Protagenic Therapeutics pays out -- of its earnings as a dividend.

Hepion Pharmaceuticals quarterly revenues are --, which are smaller than Protagenic Therapeutics quarterly revenues of --. Hepion Pharmaceuticals's net income of -$6.1M is lower than Protagenic Therapeutics's net income of -$1.4M. Notably, Hepion Pharmaceuticals's price-to-earnings ratio is -- while Protagenic Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hepion Pharmaceuticals is -- versus 0.13x for Protagenic Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Rigel Pharmaceuticals has a net margin of -- compared to Hepion Pharmaceuticals's net margin of 21.46%. Hepion Pharmaceuticals's return on equity of -- beat Rigel Pharmaceuticals's return on equity of --.

Hepion Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 3999900%. On the other hand Rigel Pharmaceuticals has an analysts' consensus of $33.74 which suggests that it could grow by 75.01%. Given that Hepion Pharmaceuticals has higher upside potential than Rigel Pharmaceuticals, analysts believe Hepion Pharmaceuticals is more attractive than Rigel Pharmaceuticals.

Hepion Pharmaceuticals has a beta of 1.688, which suggesting that the stock is 68.792% more volatile than S&P 500. In comparison Rigel Pharmaceuticals has a beta of 1.264, suggesting its more volatile than the S&P 500 by 26.398%.

Hepion Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rigel Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hepion Pharmaceuticals pays -- of its earnings as a dividend. Rigel Pharmaceuticals pays out -- of its earnings as a dividend.

Hepion Pharmaceuticals quarterly revenues are --, which are smaller than Rigel Pharmaceuticals quarterly revenues of $53.3M. Hepion Pharmaceuticals's net income of -$6.1M is lower than Rigel Pharmaceuticals's net income of $11.4M. Notably, Hepion Pharmaceuticals's price-to-earnings ratio is -- while Rigel Pharmaceuticals's PE ratio is 9.31x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hepion Pharmaceuticals is -- versus 1.69x for Rigel Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.